NKTX Nkarta Inc

$NKTX It's actually shocking to see it this low this close to data. It's back under cash value, strong management and imo strong hints that data will be good going from previous investor events. The fact data was delayed to put out a more comprehensive results also derisks it. The market seems to be dumping pre revenue stocks and the xbi is shaky so it's unfairly being beaten down. I'm adding more as RVR at these levels it too good to miss.

$NKTX I believe we’re officially a month away from clinical data being presented at ACR. The market is undervaluing it but I’m loading up even more.

$NKTX Multi-year trend line hit again. Of the technicals are correct, it should be the last touch before it sky-rockets higher.

$NKTX anyone saw the Stifel presentation? Hastings said that the safety data is good because "ACR wouldn't give you an oral presentation about safety otherwise".

$NKTX This is confusing. If there is data to be presented then why not present it now to the share holders/public. Problem with some biotechs is they think this is academia and fresh data should go to a conf or peer-reviewed first.

$NKTX be interesting to see if a late break abstract for data in other indications (egLN or pMN)is submitted for ACR.